Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer (PePiTA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00994864
Recruitment Status : Recruiting
First Posted : October 14, 2009
Last Update Posted : March 8, 2017
Information provided by (Responsible Party):
Jules Bordet Institute

Brief Summary:
The primary working hypothesis is that preoperative chemo-sensitivity testing using fluorodeoxyglucose positron emission tomography (FDG-PET) performed before and after one course of FOLFOX (folinic acid, fluorouracil, oxaliplatin) can identify the patients that will least likely have a significant benefit from adjuvant FOLFOX for stage III colon cancer. The benefit will be analyzed by correlating the preoperative FDG-PET uptake changes to the disease free and overall survival.

Condition or disease Intervention/treatment Phase
Colon Cancer Drug: FOLFOX Not Applicable

Detailed Description:

Patients with histological confirmed colon adenocarcinoma compatible with clinical stage II or III are eligible for study screening. Receipt of a signed informed consent and study inclusion should be done within 15 days after histological diagnosis. A usual workup for preoperative staging of colon cancer must be done not more than 1 month before study inclusion and include CEA assessment, positive histological sample for colon adenocarcinoma and chest and abdominal CT scan. After receipt of the written consent, the patient undergoes baseline PET/CT scan and donates blood samples for CTC and SNP analyses. Delay between baseline examinations and histological diagnosis must not exceed 21 days. The baseline examinations should be done within 1 week before beginning of the first course of FOLFOX chemotherapy. Thirteen to 15 days after chemotherapy, the PET/CT and blood sampling for CTC analysis are repeated. Standard surgery follows after 15 days but no more than 30 days from Day 1 of preoperative chemotherapy. Two frozen tissue cores are obtained during surgery and sent immediately in dry ice shipping to the central Tumour Bank (Jules Bordet Institute) or stored locally at -80°C to be sent in batches to the central tumour bank. Thereafter, the patient receives standard care, according to tumour pathological stage. In fully eligible patients, FOLFOX chemotherapy should be started not more than 45 days after surgery. In stage III patients otherwise ineligible, recommendation is to start FOLFOX chemotherapy within 45 days after surgery although such patients will not be included in the primary analysis. Treatment in case of stage II or stage IV colon cancer is left at investigator's discretion. Eleven courses of adjuvant FOLFOX are foreseen, in order to match the usual recommendation coming from the Mosaic Trial.

Follow-up procedures after completion of adjuvant treatment will follow standard European clinical recommendations for stage II and III patients. Clinical follow-up data will be obtained for all patients, including those with stage II disease, with a minimum follow-up time of three years.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 235 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial
Study Start Date : November 2009
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Arm Intervention/treatment
adjuvant FOLFOX (1 pre-operative cycle)
One cycle of preoperative standard FOLFOX chemotherapy followed by eleven cycles post-operatively. PET/CT before and after the pre-operative chemotherapy cycle.
One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
Other Name: FOLFOX-4 or equivalent

Primary Outcome Measures :
  1. Examine the predictive value of PET-assessed tumour FDG uptake response after one course of preoperative chemotherapy on the outcome of adjuvant therapy, measured by 3-year DFS. [ Time Frame: Within 3 years after completion of adjuvant chemotherapy ]

Secondary Outcome Measures :
  1. Examine the predictive value of PET-assessed tumour FDG uptake changes after one course of preoperative chemotherapy on OS [ Time Frame: Within 3 years after completion of adjuvant chemotherapy ]
  2. Evaluate the best cut-off value for relative delta SUV in assessment of preoperative chemotherapy response by FDG-PET/CT imaging. [ Time Frame: Within 3 years after completion of adjuvant chemotherapy ]
  3. Analyze the cost-effectiveness of preoperative chemo-sensitivity testing [ Time Frame: Within 3 years after completion of adjuvant chemotherapy ]
  4. Assess the predictive value of circulating tumour cells on disease-free survival [ Time Frame: Within 3 years after completion of adjuvant chemotherapy ]
  5. Assess the predictive value of SNPs on toxicity- and drug target-related genes on DFS [ Time Frame: Within 3 years after completion of adjuvant chemotherapy ]
  6. Create a frozen tumour bank for future studies [ Time Frame: Within 2 years from the beginning of study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or older
  • Clinical/radiological evaluation compatible with stage III colon adenocarcinoma
  • No prior chemotherapy
  • No prior abdominal or pelvic irradiation
  • WHO performance status 0 or 1
  • Effective contraception during the study and the following six months
  • Signed informed consent obtained prior to any study-specific screening procedures
  • Tumour considered as curatively resectable (R0) based on standard preoperative evaluations
  • White blood cell count ≥ 3×109/L with neutrophils ≥ 1.5×109/L, platelet count ≥ 100×109/L, haemoglobin ≥ 9 g/dL (5.6 mmol/L)
  • Direct bilirubin ≤ 1.5×ULN; ASAT and ALAT ≤ 2.5×ULN; Alkaline phosphatase ≤ 2.5×ULN; Serum creatinine ≤ 1.5×ULN
  • Delay between assessment of screening criteria and first PET/CT < 21 days
  • Blood glucose < 150 mg/dl at the time of FDG administration. Insulin or oral anti-diabetic medication is not allowed on the days of PET/CT imaging.
  • Compliance to the first chemotherapy course to be administered before surgery
  • Delay between the first PET/CT imaging and the start of neoadjuvant FOLOFX < 7 days
  • Second PET/CT imaging performed on D14 (range: D13-D15, with D1 as the first day of chemo administration)
  • Delay between the second PET/CT and surgery < 7 days
  • Stage III (ypTNM) as assessed after surgery
  • CEA < 1.5 x ULN 1 month after surgery -

Exclusion Criteria:

  • Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to screening. Incompletely healed wounds or anticipation of the need for major surgical procedure during the course of the study
  • Any suspicion of metastatic disease
  • Rectal cancer located within 15 cm from the anal verge by endoscopy or under the peritoneal reflection at surgery
  • Inflammatory bowel disease
  • Pregnancy (absence to be confirmed by ß-hCG blood test) or breast-feeding
  • History or current central nervous system disease or peripheral neuropathy
  • Hypersensitivity to any of the components of study treatments
  • Previous malignancy in the last five years except basal-cell carcinoma of the skin or in situ cervical carcinoma
  • Clinically relevant coronary artery disease or history of myocardial infarction in the last 6 weeks or high risk of uncontrolled arrhythmia
  • Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent
  • Any significant disease which, in the investigator's opinion, would exclude the patient from the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00994864

Contact: Alain Hendlisz, MD 2 5413541 ext 0032
Contact: Anne Denis 2 5413196 ext 0032

Clinique St-Luc Bouge Recruiting
Bouge, Belgium, 5004
Contact: Marylene Clausse, MD   
Principal Investigator: Marylene Clausse, MD         
Hôpital Erasme Recruiting
Brussels, Belgium, 1000
Contact: Jean-Luc Van Laethem, MD   
Principal Investigator: Jean-Luc Van Laethem, MD         
Jules Bordet Institute Recruiting
Brussels, Belgium, 1000
Contact: Alain Hendlisz, MD   
Contact: Anne Denis   
Principal Investigator: Alain Hendlisz, MD         
CHU Brugmann Recruiting
Brussels, Belgium, 1020
Contact: André Efira, MD   
Principal Investigator: André Efira, MD         
IRIS Etterbeek-Ixelles Recruiting
Brussels, Belgium, 1050
Contact: Jean-Pierre Kains, MD   
Principal Investigator: Jean-Pierre Kains, MD         
Clin Université St-Luc Bruxelles Recruiting
Brussels, Belgium, 1200
Contact: Marc Van Den Eynde, MD   
Principal Investigator: Marc Van Den Eynde, MD         
HIS IZZ Bracops Recruiting
Brussels, Belgium
Contact: Daniel Brenez   
Principal Investigator: Daniel Brenez         
Grand Hôpital Charleroi Recruiting
Charleroi, Belgium
Contact: JC Canon   
Principal Investigator: JC Canon         
UZ Antwerp Recruiting
Edegem, Belgium, 2650
Contact: Marc Peeters, MD   
Principal Investigator: Marc Peeters, MD         
UZ Gent Recruiting
Gent, Belgium, 9000
Contact: Stéphanie Laurent, MD   
Principal Investigator: Stéphanie Laurent, MD         
AZ Groeninge Recruiting
Kortrijk, Belgium, 8500
Contact: Philippe Vergauwe, MD   
Principal Investigator: Philippe Vergauwe, MD         
CHR Citadelle de Liege Recruiting
Liege, Belgium, 4000
Contact: Bernard Delhougne, MD   
Principal Investigator: Bernard Delhougne, MD         
CHU De Liège Recruiting
Liège, Belgium, 4000
Contact: Marc Polus, MD   
Principal Investigator: Marc Polus, MD         
Clinique St-Joseph Recruiting
Liège, Belgium, 4000
Contact: Gauthier Demolin   
Principal Investigator: Gauthier Demolin, MD         
ZNA - Jan Palfijin Recruiting
Merksem, Belgium, 2170
Contact: Joanna Vermeij, MD         
Principal Investigator: Joanna Vermeij, MD         
CHU Ambroise Paré Recruiting
Mons, Belgium, 7000
Contact: Stephane Holbrechts, Dr    32 65 4148 80   
Principal Investigator: Stephane Holbrechts, Dr         
CHR Namur Recruiting
Namur, Belgium, 5000
Contact: Thierry De Grez, MD   
Principal Investigator: Thierry De Grez, MD         
AZ Damiaan Recruiting
Oostende, Belgium, 8400
Contact: Guido Deboever, MD   
Principal Investigator: Guido Deboever, MD         
clinique St Pierre Ottignies Recruiting
Ottignies, Belgium
Contact: JC Coche   
Principal Investigator: JC Coche         
AZ Turnhout Recruiting
Turnhout, Belgium
Contact: Jos Janssens   
Principal Investigator: Jos Janssens         
Clinique Universites UCL Mont-Godinne Recruiting
Yvoir, Belgium, 5530
Contact: Lionel D'Hondt, MD   
Principal Investigator: Lionel D'Hondt, MD         
Sponsors and Collaborators
Jules Bordet Institute
Principal Investigator: Alain Hendlisz, MD Jules Bordet Institute, Brussels, Belgium

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jules Bordet Institute Identifier: NCT00994864     History of Changes
Other Study ID Numbers: PEPITA 001
EudraCT number: 2009-011445-13
First Posted: October 14, 2009    Key Record Dates
Last Update Posted: March 8, 2017
Last Verified: March 2017

Additional relevant MeSH terms:
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases